| Autor: |
SchÙtz, Florian, Stefanovic, Stefan, Mayer, Luisa, von Au, Alexandra, Domschke, Christoph, Sohn, Christof |
| Předmět: |
|
| Zdroj: |
Oncology Research & Treatment; Apr2017, Vol. 40 Issue 5, p294-297, 4p |
| Abstrakt: |
The programmed cell death-1 receptor (PD-1) is an immune checkpoint inhibitor which is expressed on the surface of immune effector cells. It is activated mainly by PD-L1 which can be expressed by all human cells. The PD-1/PD-L1 pathway plays a subtle role in maintaining peripheral T-lymphocyte tolerance and regulating inflammation. In cancer, the expression of PD-L1 seems to be one of the major immune escape mechanisms. Many studies have shown efficacy of blocking PD-1 or PD-L1 with specific antibodies like pembrolizumab or atezulizumab. In breast cancer, potential response was demonstrated in metastatic triple-negative breast cancers. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
